Capital World Investors Allogene Therapeutics, Inc. Transaction History
Capital World Investors
- $625 Billion
- Q3 2024
A detailed history of Capital World Investors transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Capital World Investors holds 6,896,552 shares of ALLO stock, worth $14.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,896,552
Previous 6,896,552
-0.0%
Holding current value
$14.1 Million
Previous $16.1 Million
20.18%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ALLO
# of Institutions
162Shares Held
134MCall Options Held
59.4KPut Options Held
113K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$38.4 Million1.25% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$33.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.33MShares$17.1 Million0.0% of portfolio
-
State Street Corp Boston, MA7.01MShares$14.4 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR6.2MShares$12.7 Million6.22% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $295M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...